Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. ConleyCarlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Dive into the research topics of 'Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I'. Together they form a unique fingerprint.